FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to the field of immunology. Claimed is the application of a monoclonal antibody against a protein of a human Fas ligand (CD95L, or Apo1L, or FasL) or its antigen-binding fragment for manufacturing a medication for the prevention and/or treatment of skin diseases, associated with the acantholysis of keratinocytes, in particular for the prevention and/or treatment of pemphigus, where the antibody contains amino acid sequences CDR of the antibody NOK-2, F919-7-3, F918-9-4 or F919-9-18 or is produced by the hybridoma ATCC PTA-5045, ATCC PTA-5533, ATCC PTA-5534 or ATCC PTA-5535.
EFFECT: application of the antibodies by the invention or their antigen-binding fragments provides the effective blocking of mechanisms, resulting in pemphigus lesions.
7 cl, 14 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| PREPARATIONS, CONTAINING ANTIBODIES AGAINST Fas LIGAND, FOR TREATING PEMPHIGUS | 2009 |
|
RU2556818C2 |
| INHIBITORS OF CD95 SIGNALING PATHWAY FOR TREATMENT OF MDS | 2013 |
|
RU2652348C2 |
| ANTI-TNFRSF25 ANTIBODIES | 2017 |
|
RU2746314C2 |
| ANTI-DR5 ANTIBODY AND USE THEREOF | 2018 |
|
RU2735956C1 |
| METHODS AND COMPOSITIONS FOR PREDICTION OF THERAPEUTIC EFFICIENCY OF TREATMENT OF ONCOLOGICAL DISEASES AND PREDICTION OF ONCOLOGICAL DISEASES | 2016 |
|
RU2785291C2 |
| ANTI-TFR ANTIBODIES AND USE THEREOF IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS | 2016 |
|
RU2737637C2 |
| ANTIBODY-DRUG CONJUGATES AND THEIR USE FOR THE TREATMENT OF CANCER DISEASES | 2019 |
|
RU2799547C2 |
| EGFL6-SPECIFIC MONOCLONAL ANTIBODIES AND THEIR APPLICATION METHODS | 2017 |
|
RU2779902C2 |
| HUMANIZED MONOCLONAL ANTIBODY AGAINST Aβ AND ITS USE | 2020 |
|
RU2783528C1 |
| NEW ANTIBODIES AGAINST XI FACTOR AND THEIR APPLICATIONS | 2017 |
|
RU2758160C2 |
